Singal-Minded

Share this post

User's avatar
Singal-Minded
This Is A Low Bar For Alzheimer’s Researchers To Trip Over
Copy link
Facebook
Email
Notes
More

This Is A Low Bar For Alzheimer’s Researchers To Trip Over

A bit more about those “easy” problems scientists stubbornly refuse to solve

Jesse Singal
Jul 21, 2023
∙ Paid
78

Share this post

User's avatar
Singal-Minded
This Is A Low Bar For Alzheimer’s Researchers To Trip Over
Copy link
Facebook
Email
Notes
More
36
3
Share

Writing in his column for i, my buddy Stuart Ritchie has a good take on the new Alzheimer’s drug donanemab, which the FDA is likely to decide whether to approve by the end of the year. On the basis of a new study just published in JAMA, donanemab is being treated as a major turning point in the fight against this neurodegenerative disease, and it comes …

Keep reading with a 7-day free trial

Subscribe to Singal-Minded to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Jesse Singal
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More